• Molecular NameCaspofungin
  • SynonymCapsofungin; Caspofungin acetate
  • Weight1093.33
  • Drugbank_IDDB00520
  • ACS_NO179463-17-3
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)N/A
  • pkaN/A
  • LogD (pH=7, predicted)N/A
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)N/A
  • LogSw (predicted, AB/LogsW2.0)N/A
  • Sw (mg/ml) (predicted, ACD/Labs)N/A
  • No.of HBond DonorsN/A
  • No.of HBond AcceptorsN/A
  • No.of Rotatable BondsN/A
  • TPSAN/A
  • StatusFDA approved
  • AdministrationIV
  • PharmacologyAn antifungal drug, the first of a new class termed the echinocandins from Merck & Co., Inc. It shows activity against infections with Aspergillus and Candida, and works by inhibiting the enzyme β(1,3)-D-Glucan synthase and thereby disturbing the integrity of the fungal cell wall.
  • Absorption_valueN/A
  • Absorption (description)92% tissue distribution within 36-48 hours after intravenous infusion
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding97.0
  • Volume of distribution (VD)0.12 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • Metabollsmtabolized slowly by hydrolysis and N-acetylation
  • Half life9.6 h
  • ExcretionN/A
  • Urinary Excretion2
  • Clerance0.16 ml/min/kg
  • ToxicitySide effects include rash, swelling, and nausea (rare)
  • LD50 (rat)N/A
  • LD50 (mouse)N/A